Isatin hybrids and their anti-tuberculosis activity

Tuberculosis (TB) is one of the most common and even fatal infectious diseases known to mankind. Millions of new cases are reported every year over the world, and one-third of the world's population is potentially infected with mycobacteria tuberculosis (MTB). Research to develop novel anti-TB drugs led to the identification of several isatin-based antimycobacterial agents, among which a number of potential candidates displayed excellent antimycobacterial activity and were found to be free of cytotoxicity. This review outlines the advances in the application of isatin hybrids as antimycobacterial agents and the critical aspects of design and structure-activity relationship of these derivatives.